Contacts

MedinCell announces a capital increase of a c.€30 million

February 10, 2021

MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company developing a portfolio of longacting injectable products in various therapeutic areas (the “Company”), announces today a capital increase of €c.30 million through an offering to qualified investors, both French and international, by way of an accelerated bookbuilding process (the “Offering”).
Bryan, Garnier & Co Limited1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.